Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…Abstract Number: 2165 • 2019 ACR/ARP Annual Meeting
Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
Background/Purpose: Chronic low back pain (cLBP) is the 2nd most common reason for physician visits; annual related costs exceed $100 billion and are expected to…Abstract Number: 2170 • 2019 ACR/ARP Annual Meeting
Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?
Background/Purpose: Low energy hip fractures are feared harbingers of morbidity and mortality. However, many older adults are high functioning and cognitively intact at the time…Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…Abstract Number: 56 • 2019 ACR/ARP Annual Meeting
Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly
Background/Purpose: Elderly-onset RA (EORA) and polymyalgia rheumatica (PMR) are common rheumatic disease in the elderly and their pathogenesis are still not completely understood. Perturbations caused…Abstract Number: 325 • 2019 ACR/ARP Annual Meeting
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a…Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…Abstract Number: 387 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis
Background/Purpose: The association between inflammatory myositis and malignancy is well established, however, the risk of malignancy in aged patients is known to be similar with…Abstract Number: 417 • 2018 ACR/ARHP Annual Meeting
Patient Reported Outcomes Pre and Post Intervention in Older Veterans with Chronic Back Pain
Background/Purpose: Chronic back pain is the second most common reason for a physician’s visit and results in significant physical and psychosocial consequences in older adults.…Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…Abstract Number: 820 • 2018 ACR/ARHP Annual Meeting
Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis – Revisited: A 20-Year Population-Based Study From Sweden
Background/Purpose: To investigate the incidence rate and seasonal variation of biopsy-proven giant cell arteritis (GCA) in a well-defined population in southern Sweden. Methods: The study…Abstract Number: 944 • 2018 ACR/ARHP Annual Meeting
Gout: A Potential Risk Factor for Uveitis in the Older Adults?
Background/Purpose: Elevated intraocular levels of these pro-inflammatory cytokines and systemic levels of C-reactive protein are seen in uveitis, which leads to 30,000 new cases of…Abstract Number: 1133 • 2018 ACR/ARHP Annual Meeting
Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients
Background/Purpose: Current guidelines for osteoarthritis (OA) treatment recommend a range of nonpharmacological and pharmacological interventions to alleviate pain, improve function and quality of life. Most…Abstract Number: 1475 • 2018 ACR/ARHP Annual Meeting
Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly
Background/Purpose: Elderly-onset RA, EORA, which is defined as rheumatoid arthritis (RA) starting at >60 years of age, has received less attention than young-onset RA. Polymyalgia rheumatica (PMR) is…Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
- 1
- 2
- 3
- …
- 5
- Next Page »